Identification of GNA12-driven gene signatures and key signaling networks in ovarian cancer

JI-HEE HA12*, MURALIDHARAN JAYARAMAN1,2*, MINGDA YAN1*, PADMAJA DHANASEKARAN1, CIRO ISIDORO3, YONG-SANG SONG4 and DANNY N. DHANASEKARAN1,2

1Stephenson Cancer Center, The University of Oklahoma Health Sciences Center; 2Department of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA; 3Laboratory of Molecular Pathology and NanoBioImaging, Department of Health Sciences, University of Eastern Piedmont, I-17-28100 Novara, Italy; 4Department of Obstetrics and Gynecology, Cancer Research Institute, College of Medicine, Seoul National University, Seoul 151-921, Republic of Korea

Received April 20, 2021; Accepted July 16, 2021

DOI: 10.3892/ol.2021.12980

Abstract. With the focus on defining the oncogenic network stimulated by lysophosphatidic acid (LPA) in ovarian cancer, the present study sought to interrogate the oncотranscriptome regulated by the LPA-mediated signaling pathway. LPA, LPA-receptor (LPAR) and LPAR-activated G protein 12 α-subunit, encoded by G protein subunit α 12 (GNA12), all serve an important role in ovarian cancer progression. While the general signaling mechanism regulated by LPA/LPAR/GNA12 has previously been characterized, the global transcriptomic network regulated by GNA12 in ovarian cancer pathophysiology remains largely unknown. To define the LPA/LPAR/GNA12-orchestrated oncogenic networks in ovarian cancer, transcriptomic and bioinformatical analyses were conducted using SKOV3 cells, in which the expression of GNA12 was silenced. Array analysis was performed in Agilent SurePrint G3 Human Comparative Genomic Hybridization 8x60 microarray platform. The array results were validated using Kuramochi cells. Gene and functional enrichment analyses were performed using Database for Annotation, Visualization and Integrated Discovery, Search Tool for Retrieval of Interacting Genes and Cytoscape algorithms. The results indicated a paradigm in which GNA12 drove ovarian cancer progression by upregulating a pro-tumorigenic network with AKTI, VEGFA, TGFβ1, BCL2L1, STAT3, insulin-like growth factor 1 and growth hormone releasing hormone as critical hub and/or bottleneck nodes. Moreover, GNA12 downregulated a growth-suppressive network involving proteasome 20S subunit (PSM) β6, PSM α6, PSM ATPase 5, ubiquitin conjugating enzyme E2 E1, PSM non-ATPase 10, NDUFA4 mitochondrial complex-associated, NADH:ubiquinone oxidoreductase subunit B8 and anaphase promoting complex subunit 1 as hub or bottleneck nodes. In addition to providing novel insights into the LPA/LPAR/GNA12-regulated oncogenic networks in ovarian cancer, the present study identified several potential nodes in this network that could be assessed for targeted therapy.

Introduction

Ovarian cancer is the seventh most common cancer type in women worldwide, with 250,000 new cases diagnosed worldwide annually, and it lead to 185,000 deaths in 2020 (1). Recent analysis has estimated that the deaths associated with ovarian cancer would be as high as 13,770 by 2021 in the USA alone (2). The high mortality rate in ovarian cancer is associated with a late diagnosis, as well as a lack of an effective targeted therapy (3,4).

The observation that lysophosphatidic acid (LPA) synthesized by cancer cells acts as an endogenous growth factor, and that LPA-mediated signaling pathways serve a tumor-promoting role across numerous cancer types, including ovarian cancer, is clinically significant (5,6). LPA was initially identified as a platelet derived bioactive phospholipid that stimulated the proliferation of fibroblasts involved in wound healing (7). Subsequent studies have shown that LPA stimulates multiple signaling pathways underlying cell proliferation, migration, and survival via specific G-protein coupled receptors and the associated heterotrimeric G proteins (8,9). Of the different G proteins that could be activated by LPA-receptors (LPARs), G protein 12 (G12) has been identified as the major conduit involved in LPA-mediated mitogenic signaling (10-12). In
ovarian cancer, cancer cells synthesize and release LPA into the tumor microenvironment (TME). LPA present in the TME promotes cancer progression and metastasis via the activation of specific LPA-receptors (LPARs) that are present in multicellular components of the TME (13,14). In cancer cells, LPA stimulates an autocrine signaling loop via the activation of cancer cell-bound G-protein coupled LPARs. Although G protein coupled receptors, such as LPARs, have proven to be highly amenable for drug development, targeting LPARs in ovarian cancer has been challenging. High concentrations of LPA in the intraperitoneal ascites surrounding the ovarian cancer tissue and the close proximity of the LPA-synthetic machinery to LPARs on the surface of ovarian cancer cells have impeded LPAR-targeted therapeutic strategies in ovarian cancer. Recent studies from several laboratories, including ours, have reported that the α-subunit of the oncogene G-protein G12, encoded by the gene G protein subunit α 12 (GNA12), is the major conduit involved in transmitting oncogenic signals in numerous cancer types, including ovarian cancer (15-20). It has been revealed that either LPAR-stimulated activation or mutational activation of GNA12, referred to as the gep oncogene, induces the oncogenic proliferation of ovarian cancer cells (15,16).

Tumorigenesis and tumor progression often involve the deregulation of multiple pathways, impacting a cell-wide signaling network rather than an alteration in a single gene or pathway (21). Therefore, we hypothesized that the transcriptomic analysis based on the aggregated expression of genes associated with multiple pathways co-regulated by GNA12 could provide additional insights into the activation of specific LPA-receptors (LPARs) that are present in multicellular components of the TME (13,14). In cancer cells, LPA stimulates an autocrine signaling loop via the activation of cancer cell-bound G-protein coupled LPARs. Although G protein coupled receptors, such as LPARs, have proven to be highly amenable for drug development, targeting LPARs in ovarian cancer has been challenging. High concentrations of LPA in the intraperitoneal ascites surrounding the ovarian cancer tissue and the close proximity of the LPA-synthetic machinery to LPARs on the surface of ovarian cancer cells have impeded LPAR-targeted therapeutic strategies in ovarian cancer. Recent studies from several laboratories, including ours, have reported that the α-subunit of the oncogene G-protein G12, encoded by the gene G protein subunit α 12 (GNA12), is the major conduit involved in transmitting oncogenic signals in numerous cancer types, including ovarian cancer (15-20). It has been revealed that either LPAR-stimulated activation or mutational activation of GNA12, referred to as the gep oncogene, induces the oncogenic proliferation of ovarian cancer cells (15,16).

Transfection methods. Silencing of GNA12 in SKOV3 cells was carried out as described in our previously publication (16). Briefly, non-target scrambled control shRNA pLKO.1 vector construct (Sigma-Aldrich; Merck KGaA (SHC002) and pLKO.1 vector construct targeting GNA12/Ga12 (HGSH3979-98491914; Open Biosystems) were stably transfected into SKOV3 cells using Amaxa Biosystems Nucleofector II, according to the instructions of the manufacturer. The stably transfected NS control and Ga-silenced clones were selected with puromycin (2 µg/ml; MP Biomedicals) and single clones were picked, expanded to obtain stable cell lines. Prior to the array analysis, the silencing of GNA12-expression was ascertained by immunoblot analysis. Silencing of GNA12 in Kuramochi cells were carried out using siRNAs targeting GNA12 (siGENOME Human GNA12 siRNA SMARTpool; cat. no. M-008435-00-0005) and non-targeting scrambled control siRNAs control (siGENOME Non-Targeting siRNA Pool; cat. no. D-001206-13-05) were obtained from Dharmacon/Horizon Discovery. Kuramochi cells were transfected with siRNA using Lipofectamine RNAiMAX reagent (Invitrogen, Life Technologies) as recommended by the manufacturer. Kuramochi cells were seeded in 6-well plates at a density of 1x10⁵ cells per well and incubated for 24 h. Lipofectamine RNAiMAX reagent (9 µl) in 300 µl of Opti-MEM (Invitrogen, Life Technologies) was incubated for 5 min at room temperature. siRNA was added to the Opti-MEM-lipofectamine RNAiMAX solution to a final concentration of 100 nM. The mixture was added to the cell culture, and after 48 h incubation for gene silencing, the cells were collected for RT-qPCR analysis. Expression of GNA12 in the transfectedants was monitored by short tandem repeat analysis as described (13). Kuramochi cells were maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Cellgro) and SKOV3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Cellgro), both at 37°C in a 5% CO₂ incubator. In both cases, the media were supplemented with 10% FBS (Gemini Bio-Products), 50 U/ml penicillin, 50 µg/ml streptomycin (Cellgro). For LPA-stimulation studies, 18.1 LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate; cat. no. 85730), was obtained from Avanti Polar Lipids (Alabaster, AL). LPA was dissolved in 10 mM stock solutions in phosphate buffered saline containing 1% BSA and stored at -80°C until use.

Human cell lines and methods used in this study were approved by the Institutional Review Board for the protection of the Human Subjects of the University of Oklahoma (approval no. 9599).

Transcriptomic analysis. Transcriptome profiles were obtained using Agilent SurePrint G3 Human Comparative Genomic Hybridization 8x60 microarray platform. SKOV3-shScr (non-specific scrambled shRNA control) and SKOV3-shGNA12 cells were cultured for 24 h, followed by 16 h of serum starvation. These cells were stimulated with LPA (10 µM) for 16 h and total RNA was extracted using Qiagen RNeasy mini kit (Qiagen) following the manufacturer's protocol. Agilent QuickAmp labeling kit was used to label RNA samples with Cy3-CTP and hybridized to the array slides following the manufacturer's protocol. The hybridized
array slides were scanned using Agilent SureScan scanner at 2 microns resolution. The spot intensity was extracted using Agilent Feature Extraction version 11.0 software. Further, gene expression analysis was carried out using Agilent GeneSpring GX version 13.0. Differentially expressed genes (DEGs), with a cut-off value of ±5-fold change compared to control cells, were used for further bioinformatic analyses.

Bioinformatics analysis. Gene ontology Enrichment analysis of the DEGs was carried out using the web-based annotation tool DAVID (https://david.ncifcrf.gov/home.jsp) (22). Protein-Protein Interaction Networks Functional Enrichment Analysis was carried out using web-based (https://string-db.org/) STRING database (23). The upregulated genes and downregulated genes were analyzed separately with the highest confidence interaction score (0.9) and <10 degree of interaction. Significant modules in the PPI network was identified using the cytoHubba plugin in Cytoscape (25). Multiple algorithms of cytoHubba including Degree, Maximal Clique Centrality and (MCC), maximum neighbourhood component (MNC), Edge Percolated Component (EPC), Eccentricity, Closeness, Betweenness, and Clustering Coefficient were used to identify the hub nodes of the PPI networks (26). BottleNeck algorithm of cytoHubba was used to identify the bottleneck nodes of the network.

RT-qPCR analysis. Total RNA was extracted using Qiagen RNeasy kit (Qiagen) following the manufacturer’s instructions. cDNA synthesis was carried out using an iScript™ cDNA Synthesis Kit (Bio-Rad). Real-time quantitative PCR (RT-qPCR) was carried out using the cDNA from the above step using appropriate primers (Table SI) and SoAdvanced Universal SYBR Green Supermix (Bio-Rad) in a BioRad CFX96 Real time PCR detection system. The raw Cq values were normalized against GAPDH, housekeeping gene.

Immunoblot analysis. Antibodies to GNA12 (sc-409), GAPDH (CB1001), peroxidase-conjugated anti-rabbit IgG (W401B) were obtained from Santa Cruz Biotechnology Inc., Abcam and Promega Corporation, respectively. Immunoblot analysis was carried out according to our previously published methods (12) and developed with a Kodak Image Station 4000 MM.

Statistics. All required statistical analyses were performed using GraphPad Prism by two-tailed unpaired Student’s t-test with Welch’s correction. Statistics used in bioinformatics such as P-values and False Discovery Rates were calculated using the built-in statistical programs of the respective analytical tools.

Results

Identification of DEGs. Our previous studies have shown that LPA/LPAR stimulates ovarian cancer growth and cell proliferation via the activation of GNA12, encoded by the gene GNA12 or its mutationally activated configuration known as the gep oncogene (15,16). To obtain an understanding of the transcriptomic network regulated by GNA12, the expression of GNA12 was silenced in SKOV3 cells using shRNAs targeting GNA12. These cells were stimulated with LPA and the DEGs in GNA12-silenced cells compared with those in the scrambled shRNA control group were identified using an Agilent array. With a cut-off value of ±5-fold change, compared with control cells, GNA12-silenced cells had 313 downregulated genes and 293 upregulated genes (Fig. 1A and B). Of the 313 downregulated genes, 145 genes were found to be protein-encoding genes (Table SII). Similarly, among the 293 upregulated genes, 186 genes were found to be protein-encoding genes (Table SIII). Other genes were represented by either long non-coding RNAs or pseudogene transcripts (Tables SIV).

Next, the current study aimed to validate the array results in a cell lines that represent high grade ovarian serous ovarian carcinoma (HGSOC). The expression of GNA12 was silenced in Kuramochi cells, a HGSOC cell line, using specific siRNAs targeting GNA12. After determining the efficacy of GNA12 silencing in these cells (Fig. 1C), RT-qPCR analysis was conducted to validate the expression levels of the DEGs. Downregulated genes were validated by monitoring the expression levels of the representative growth-promoting genes ankaryin repeat domain 1 (ANKRD1), bone marrow stromal cell antigen 2 (BST2) and cancer antigen 1 (CAGE1), whereas the upregulated genes were validated by monitoring the expression levels of growth-repressive representative genes, namely autophagy-related 16-like 1 (ATG16L1), spindlin family member 3 (SPIN3), thrombopoietin (THPO) and tetraspanin 16 (TSPAN16). It was found that silencing of GNA12 led to the decreased expression of ANKRD1, BST2 and CAGE1 (Fig. 1D), along with the increased expression of ATG16L1, SPIN3, THPO and TSPAN16, thereby validating the array results (Fig. 1E).

GO enrichment analysis of DEGs. It should be noted that the genes downregulated after silencing of GNA12 represent the genes whose expression was induced by GNA12, whereas the upregulated genes represent the genes whose expression was repressed by GNA12 in situ. Therefore, defining the functional relationships among the downregulated as well as the upregulated DEGs could provide insights into the mechanism via which GNA12 promotes ovarian cancer progression. Since GO enrichment analysis can provide information on the functional relationship among a large set of genes, GO analysis under the three sub-ontologies, namely biological processes (GO:BP), molecular functions (GO:MF) and cellular components (GO:CC), was conducted. GO enrichment analyses of the DEGs were performed using the web-based DAVID analytical tool (22). In GO:BP, the upregulated genes were significantly enriched in BP involving ‘cell adhesion’, ‘proliferation’ and ‘cell motility’ (Table I). These BP were associated with the known oncogenic functions of GNA12 in oncogenic cell proliferation and migration. In GO:CC, CC including ‘plasma membrane’ and ‘actin-based cellular projections’ formed the major categories, which was consistent with the role of GNA12 in actin cytoskeletal reorganization underlying cell invasion (20). In GO:MF, the topmost enriched categories were ‘macromolecular interaction’, ‘chromatin and nucleic acid interaction’ and ‘transcriptional activation’ (Table I), thus...
validating the role of GNA12-mediated network in molecular interactions leading to oncogenic transcriptional events.

With regards to genes that were downregulated in GNA12-silenced cells, GO:BP showed enrichment of categories associated with the overall negative regulation of cellular and BP including different aspects of ‘cell death’ and ‘proteolytic processes’ that can be linked with growth-inhibition (Table II). In GO:CC, the enriched categories included ‘membrane components of the cells’ and components associated with ‘autophagosome membrane’ and ‘extracellular matrix’. This finding was in agreement with the notion that the primary site of action of GNA12 is closer to cell surface membrane (27). In GO:MF, the enriched categories were associated with ‘protein binding’ and peptidase functions including ‘exopeptidase’, ‘metallopeptidase’ and ‘metalloexopeptidase’ (Table II), which are often associated with programmed cell death (28).

Analysis of PPI networks and pathways. To further investigate the functional interactions among the proteins encoded by the DEGs, PPI network functional enrichment analysis was conducted using the STRING database (23). The upregulated and downregulated genes were analyzed separately, with the highest confidence interaction score (0.9) and <10 degrees of interaction. The PPI network downregulated in GNA12-silenced cells was constructed by screening 186 nodes and 306 edges (Fig. 2). The most significant module in the PPI network was determined using Cytoscape software (24). Kyoto Encyclopedia of Genes and Genomes

Figure 1. Heatmap of the DEGs and validation. (A) Validation of shRNA-mediated GNA12-silencing in SKOV3 cells. Expression of GNA12 was stably silenced in SKOV3 cells using shGNA12 compared with control cells stably expressing non-targeting scrambled shRNAs. (B) Heatmap of the DEGs; the ratio comparing control cells (scrambled shRNA) and GNA12-silenced cells is presented as a heat map. Red, black and green colors represent upregulated, unchanged and downregulated expression, respectively. Total number of DEGs with >5-fold-change compared with control values and the number of downregulated and upregulated DEGs are presented as a table. (C) Array results were validated by RT-qPCR using siRNA-mediated GNA12-silenced Kuramochi cells compared with non-targeting scrambled siRNA controls. (D) Downregulated DEGs were validated by monitoring the expression of the representative genes ANKRD1, BST2 and CAGE1 by RT-qPCR. (E) Expression of the upregulated DEEGs was validated by monitoring the expression of the representative upregulated genes ATG16L1, SPIN3, THPO, and TSPAN16 by RT-qPCR. "P<0.05, **P<0.005, ***P<0.0005. DEGs, differentially expressed genes; sh, short hairpin; GNA12, G protein subunit α12; Scr, scrambled; RT-qPCR, CON, control; ANKRD1, ankyrin repeat domain 1; BST2, bone marrow stromal cell antigen 2; CAGE1, cancer antigen 1; RT-qPCR, reverse transcription-quantitative PCR; ATG16L1, autophagy-related 16-like 1; SPIN3, spindlin family member 3; THPO, thrombopoietin; TSPAN16, tetraspanin 16.
(KEGG) analyses indicated that the major pathways defined by GNA12-dependent genes were pathways involved in ‘cancer’, ‘PI3K/AKT signaling’, ‘chemotherapy resistance’ and ‘FoxO signaling’ (Table III). Reactome analysis expanded this further into pathways associated with signaling involving ‘tyrosine kinases’, ‘VEGF signaling’, ‘PI3K/AKT signaling’, ‘cell surface interactions at the vascular wall’, ‘cancer associated aberrant signaling by PI3K’ and ‘signaling by receptor tyrosine kinases’ (Table III).

A similar PPI network construction was performed with the genes upregulated after silencing of GNA12 by screening a total of 202 nodes and 964 edges from the STRING portal (Fig. 3). KEGG pathway analyses indicated that the network, which was repressed by GNA12, was primarily involved in ‘metabolism’, ‘oxidative phosphorylation’, ‘proteasomal proteolysis’, ‘cell cycle arrest’ and ‘transcriptional misregulation in cancer’ (Table IV). Reactome pathways analysis revealed that pathways regulated in this network included ‘metabolism of proteins’, ‘cell cycle checkpoints’, ‘cellular stress response’, ‘anaphase-prophase complex (APC/C) mediated degradation of mitotic proteins’ and ‘ubiquitin-dependent degradation of cyclin D’, all of which could be associated with growth-inhibition (Table IV).

Identification of the hub and bottleneck nodes. The network was further analyzed to identify the critical genes that define the hub nodes of the PPI network using the cytoHubba plugin in Cytoscape (25). The multiple algorithms of the cyto-Hubba, including Degree, MCC, MNC, EPC, Eccentricity, Closeness, Betweenness and Clustering Coefficient, were used to identify the hub nodes of the PPI networks (26). The intersecting genes identified by the different algorithms were tabulated (Table V). Results from this analysis identified AKT1, VEGFA, BCL2L1, TGFB1 and STAT3 as the top five hub nodes (Fig. 2, Insert; Table V). In addition to hub nodes, the identification of bottleneck nodes has equal or more importance in PPI networks due to their role as the key ‘connector proteins’ (29,30). Therefore, the bottleneck nodes of the network were extracted using the BottleNeck algorithm in cytoHubba application of Cytoscape. The results demonstrated that VEGFA, AKT1 and STAT3 were defined the bottleneck nodes, in addition to IGF1 and GHRH (Fig. 2, Insert).

A similar analysis was conducted to extract the hub nodes and the bottleneck nodes of the upregulated genes. The results identified proteasome 20S subunit (PSM) β 6 (PSMB6), PSM α 6 (PSMA6), PSM ATPase 5 (PSMC5), ubiquitin conjugating enzyme E2 E1 (UBE2E1) and PSM non-ATPase 10 (PSMD10),

Table I. GO enrichment analysis of downregulated genes in GNA12-silenced cells.

| Term                      | Description                          | Gene count | P-value  |
|---------------------------|--------------------------------------|------------|----------|
| GO:0048518                | Positive regulation of Biological Process | 45         | 6.3x10^2 |
| GO:0048583                | Regulation of response to Stimulus    | 24         | 8.7x10^2 |
| GO:0007155                | Cell adhesion                        | 21         | 2.1x10^2 |
| GO:0008283                | Cell proliferation                   | 19         | 4.9x10^1 |
| GO:0048870                | Cell motility                        | 15         | 4.9x10^1 |

| Term                      | Description                          | Gene count | P-value  |
|---------------------------|--------------------------------------|------------|----------|
| GO:0005886                | Plasma membrane                      | 45         | 6.7x10^2 |
| GO:0071944                | Cell periphery                       | 45         | 9.0x10^2 |
| GO:0005576                | Extracellular region                 | 42         | 4.8x10^2 |
| GO:0042995                | Cell projection                      | 18         | 9.3x10^2 |
| GO:0098862                | Cluster of actin-based cell projections | 4        | 7.8x10^2 |

| Term                      | Description                          | Gene count | P-value  |
|---------------------------|--------------------------------------|------------|----------|
| GO:0044877                | Macromolecular complex binding       | 15         | 6.0x10^2 |
| GO:0001067                | Regulatory region nucleic acid binding | 10     | 9.4x10^2 |
| GO:0000981                | Transcription factor activity        | 9          | 8.5x10^2 |
| GO:0003982                | Chromatin binding                    | 8          | 5.7x10^2 |
| GO:0001228                | Transcriptional activator activity   | 6          | 7.2x10^2 |

GO, Gene Ontology; GNA12, G protein subunit α 12.
the genes involved in proteasomal proteolysis, as the hub nodes (Fig. 3, Insert; Table VI). PSMA6 and PSMB6 were also identified as bottleneck nodes, along with NDUFA4 mitochondrial complex associated (NDUFA4), NADH:ubiquinone oxidoreductase subunit B8 (NDUFB8) and anaphase promoting complex subunit 1 (ANAPC1) genes (Fig. 3, Insert; Table VI).

Biological significance of the hub and bottleneck nodes. The biological significance of the hub and bottleneck node genes in relation to ovarian cancer was determined via cBioPortal analysis (31,32). First, the hub and bottleneck genes downregulated in GNA12-silenced cells were examined (Table V). The oncoprint profile of these genes indicated that they were either amplified or upregulated in at least 4-10% of the patients with ovarian cancer (Fig. 4). Functional annotation of these genes, as shown in Table V, indicated that the aberrant increased expression of these genes was associated with cancer growth, progression, metastasis and therapy resistance in ovarian cancer (33-45).

Next, the hub and bottleneck genes upregulated in GNA12-silenced cells were examined (Table VI). These nodes, representing the genes that would have been suppressed by GNA12, were found to be associated with proteasome-mediated context-specific apoptotic pathways and therapy resistance in numerous cancer types (46-57). Taken together, the functional analyses of the hub and bottleneck genes indicated that the genes downregulated in GNA12-silenced cells coded for pro-tumorigenic proteins, while the genes upregulated upon silencing of GNA12 encoded anti-tumorigenic proteins (Fig. 5).

Discussion

Autocrine and paracrine signaling by LPA serve a determinant role in cancer development and progression, and this is evident in the context of ovarian cancer (15,16). Our previous studies have reported that activation of GNA12 by LPA/LPAR signaling or mutational activation of GNA12 into the gep oncogene serve a critical role in the oncogenic proliferation of ovarian cancer cells (15,16). In the present study, the key signaling pathways and critical genetic nodes that are aberrantly regulated by LPA/LPAR/GNA12 signaling in ovarian cancer were identified. In the cellular model used, the genes that were downregulated upon silencing of GNA12 represent the genes that would be upregulated by an intact LPA/LPAR/GNA12 signaling pathway, whereas the genes that were upregulated upon silencing

Table II. GO enrichment analysis of upregulated genes in GNA12-silenced cells.

| Term                  | Description                        | Gene count | P-value |
|-----------------------|------------------------------------|------------|---------|
| GO:0048519            | Negative regulation of biological process | 46         | 6.4x10² |
| GO:0048523            | Negative regulation of cellular process | 45         | 3.2x10² |
| GO:0006508            | Proteolysis                        | 20         | 7.5x10² |
| GO:0010941            | Regulation of cell death            | 18         | 8.8x10¹ |
| GO:0042981            | Regulation of apoptotic process     | 17         | 8.7x10¹ |

B, GO: Cellular component

| Term                  | Description                        | Gene count | P-value |
|-----------------------|------------------------------------|------------|---------|
| GO:0016020            | Membrane                           | 85         | 4.9x10² |
| GO:0071944            | Cell periphery                     | 51         | 5.8x10² |
| GO:0005886            | Plasma membrane                    | 50         | 5.9x10² |
| GO:0031012            | Extracellular matrix               | 10         | 2.3x10² |
| GO:0000421            | Autophagosome membrane             | 3          | 2.0x10² |

C, GO: Molecular function

| Term                  | Description                        | Gene count | P-value |
|-----------------------|------------------------------------|------------|---------|
| GO:0005488            | Binding                            | 122        | 9.6x10² |
| GO:0008233            | Peptidase                          | 10         | 9.8x10² |
| GO:0008237            | Metallopeptidase                   | 5          | 6.1x10² |
| GO:0008238            | Exopeptidase                       | 4          | 5.5x10² |
| GO:0008235            | Metalloexopeptidase                | 3          | 8.9x10² |

GO, Gene Ontology; GNA12, G protein subunit α 12.
GNA12 represent the genes that would be suppressed by this signaling pathway. The array analyses results indicated that genes that were upregulated by GNA12 (downregulated in GNA12-silenced cells) were mostly pro-tumorigenic, while genes that were downregulated by GNA12 (upregulated in GNA12-silenced cells) were growth-inhibitory. These array results were corroborated by the findings demonstrating that GNA12 silencing decreased the expression of pro-tumorigenic genes, along with a coincident increase in the expression of growth-suppressive genes. ANKRDI1, BST1 and CAGE1 have been previously shown to have oncogenic role in different cancer types, including ovarian cancer. ANKRDI1 has been revealed to promote drug-resistance and epithelial-mesenchymal transition (EMT) in multiple cancer cells, including ovarian cancer cells (58,59). Moreover, BST1 has been observed to induce EMT in ovarian cancer cells (59,60), while CAGE1 is known to promote both proliferation and migration in different cancer cells (61). By contrast, the genes upregulated upon silencing of GNA12, have been shown to exert a tumor suppressive role in different cancer types. For example, SPIN3 has been identified as a tumor suppressor gene that induces apoptosis in human seminoma cancer cells (62). Furthermore, ATG16L1 has been reported to be involved in promoting autophagic cell death in ovarian cancer cells (63). THPO, encoded by THPO, has also been observed to induce apoptosis in a context specific manner (64). While the cellular function of TSPAN16 remains to be fully defined, its weak expression profile in cancer cells has been considered to be indicative of its tumor suppressing potential (65). Collectively, GNA12 appears to stimulate a pro-tumorigenic network, along with the simultaneous suppression of a growth-inhibitory network.

The synergistic network organization was further clarified by the current results from the GO enrichment analyses. While GO enrichment in CC was in accordance with the known
role of GNA12 in transmitting the plasma membrane-located LPA/LPAR signaling from the cell periphery, novel insights could be gained via the analyses of GO BP and MF. The GO:BP enrichment indicated that the pathways upregulated by GNA12, thus downregulated in GNA12-silenced cells, were associated with critical BP and MF associated with cancer progression, metastasis and therapy resistance. In fact, GO:BP, such as ‘positive regulation of biological process’ (GO:0048518), has already been shown to be associated with chemoresistance in HGSOC (55). Other GO:BP, such as ‘cellular response to stimulus’ (GO:0048583), ‘cell adhesion’ (GO:0007155), ‘cell proliferation’ (GO:00008283) and ‘cell

| Term                           | Description                     | Gene count | False discovery rate |
|--------------------------------|---------------------------------|------------|----------------------|
| hsa05200                       | Pathways in cancer              | 28         | 2.43x10^{11}         |
| hsa04151                       | PI3K-AKT signaling pathway      | 18         | 2.34x10^{7}          |
| hsa01524                       | Platinum drug resistance        | 13         | 5.69x10^{11}         |
| hsa01521                       | EGFR tyrosine kinase inhibitor resistance | 13     | 2.35x10^{9}         |
| hsa04068                       | FoxO signaling pathway          | 9          | 3.60x10^{8}          |

GNA12, G protein subunit α12.

Table IV. Pathway analysis of upregulated genes in GNA12-silenced cells.

A, Kyoto Encyclopedia of Genes and Genomes pathway

| Term      | Description                              | Gene count | False discovery rate |
|-----------|------------------------------------------|------------|----------------------|
| hsa-0110  | Metabolic pathways                       | 34         | 5.57x10^{6}          |
| hsa00190  | Oxidative phosphorylation                | 26         | 1.79x10^{22}         |
| hsa03050  | Proteasome                               | 24         | 5.40x10^{29}         |
| hsa04218  | Cell cycle                               | 12         | 2.25x10^{13}         |
| hsa05202  | Transcriptional misregulation in cancer  | 7          | 2.32x10^{4}          |

B, Reactome pathway

| Term      | Description                              | Gene count | False discovery rate |
|-----------|------------------------------------------|------------|----------------------|
| HSA-392499| Metabolism of proteins                   | 40         | 7.46x10^{3}          |
| HSA-69620 | Cell cycle check points                  | 33         | 6.55x10^{24}         |
| HSA-5668541| Cellular responses to stress            | 35         | 2.69x10^{21}         |
| HSA-174178| APC/C:Cdh1 mediated degradation of Cdc20 and other | 30     | 8.83x10^{35}         |
| APC/C:Cdh1 targeted proteins in late/early mitosis |             |             |                      |
| HSA-75815 | Ubiquitin mediated degradation of cyclin D | 27         | 2.49x10^{13}         |

APC/C, anaphase-promoting complex; Cdh, CDC20 homolog; GNA12, G protein subunit α12.

Table III. Pathway analysis of downregulated genes in GNA12-silenced cells.

A, Kyoto Encyclopedia of Genes and Genomes pathway

| Term      | Description                              | Gene count | False discovery rate |
|-----------|------------------------------------------|------------|----------------------|
| hsa0906934 | Signaling by receptor tyrosine kinases    | 24         | 1.29x10^{8}          |
| HSA-194138   | Signaling by VEGF                         | 12         | 7.95x10^{8}          |
| HSA-2219528   | PI3K/AKT signaling in cancer             | 10         | 9.32x10^{7}          |
| HSA-202733   | Cell surface interactions at the vascular wall | 9          | 1.70x10^{4}         |
| HSA-2219530   | Constitutive signaling by aberrant PI3K in cancer | 7          | 7.17x10^{5}         |

B, Reactome pathway

| Term      | Description                              | Gene count | False discovery rate |
|-----------|------------------------------------------|------------|----------------------|
| HSA-392499 | Metabolism of proteins                   | 40         | 7.46x10^{3}          |
| HSA-69620 | Cell cycle check points                  | 33         | 6.55x10^{24}         |
| HSA-5668541| Cellular responses to stress            | 35         | 2.69x10^{21}         |
| HSA-174178 | APC/C:Cdh1 mediated degradation of Cdc20 and other | 30     | 8.83x10^{35}         |
| APC/C:Cdh1 targeted proteins in late/early mitosis |             |             |                      |
| HSA-75815 | Ubiquitin mediated degradation of cyclin D | 27         | 2.49x10^{13}         |
motility’ (GO:0048870), have been associated with cancer growth, recurrence and therapy resistance in numerous cancer types (56,57,66,67). Together with the indicated functions in GO:MF enrichments, the current novel findings emphasize the oncogenic role of GNA12 in transmitting signals from the LPA/LPAR signaling pathway located in the cellular periphery to a set of highly consequential nuclear events. Another significant analytical suggestion from the results was that genes suppressed by GNA12, as evidenced by their upregulation in GNA12-silenced cells, show GO enrichments in BP and MF associated with ‘negative regulation of cell growth processes’. The GO:MF enrichment also suggested the potential role of GNA12 in suppressing proteolysis associated with negative cell proliferative.

Ovarian cancer is characterized by a heterogeneous histopathology with the manifestation of dissimilar genetic and pathway alterations. Major pathways that are aberrantly altered in a range of subtypes include TP53 (68,69), PI3K/AKT (70-72), VEGF (73,74), EGFR (75,76) and FoxO signaling (77). It was significant that KEGG and Reactome pathway analyses of the DEGs upregulated in GNA12-silenced cells directly linked GNA12 to these multiple tumor-promoting pathways. KEGG and Reactome pathways upregulated in GNA12-silenced cells involved pathways associated with cell cycle check points, including ‘APC/C mediated proteasomal degradation of mitotic proteins’. Thus, the pathway analyses present an oncogenic paradigm orchestrated by GNA12 in which mutational or LPA/LPAR activation of GNA12 leads to the stimulation of a pro-tumorigenic network, while concurrently suppressing an anti-tumorigenic network involving anti-mitotic, anti-proliferative and cellular stress pathways. This was further substantiated by the analysis of the hub and bottleneck signaling nodes derived from the PPI networks of the DEGs, especially the ones that were downregulated in GNA12-silenced cells. In line with the oncogenic role of GNA12, these genes were upregulated in distinct subsets of patients with ovarian cancer and were critically involved in ovarian cancer pathobiology. AKT1 gene is frequently upregulated in ovarian cancer and is associated with paclitaxel resistance in patients with ovarian cancer (33). Furthermore, the upregulation of VEGFA has been shown to be associated with distant metastasis and resistance to chemotherapy in patients with ovarian cancer (34-36). Increased expression of TGB1 has been correlated with EMT, tumor growth and metastasis in ovarian cancer (37,38), while overexpression of BCL2L1 is associated with anti-apoptosis effects and

Figure 3. PPI network of upregulated genes. A PPI network of the genes upregulated in GNA12-silenced cells is presented. Colored nodes represent the query proteins and first shell interaction and white nodes denote second shell interactions. Nodes of similar color identifies the specific cluster of interacting nodes. Predicted functional interactions are indicated by the connecting lines. The colors of the lines represent the types of evidence that were used to predict the PPI associations as follows: Red, known gene fusions; green, gene neighborhood; blue, gene co-occurrence; purple, experimental data; yellow, text-mining; light blue, protein homology; aqua marine, curated database; and black, co-expression. Hub and bottleneck nodes of the PPI network derived from the use of cytoHubba plugin in Cytoscape application are presented as the inset. PPI, protein-protein interaction; GNA12, G protein subunit α12; UBE2E1, ubiquitin conjugating enzyme E2 E1; PSM, proteasome 20S subunit; NDUFA4, NDUFA4 mitochondrial complex-associated; NDUFB8, NADH:ubiquinone oxidoreductase subunit B8; ANAPC1, anaphase promoting complex subunit 1.
platinum resistance (39,40). In addition, STAT3 signaling in ovarian cancer has been reported to be associated with tumor cell proliferation, survival, stemness and angiogenesis (41), while the overexpression of IGF1 has been revealed to stimulate the proliferation of ovarian cancer cells, along with its immunosuppressive role in ovarian cancer (42,43). In a similar manner, GHRH, which is endogenously produced in ovarian cancer cells, is involved in ovarian cancer growth and tumor vascularization (44,45). The oncogenic role for these genes has also been shown by the oncoprint profiles of these genes generated using the CBioPortal. In fact, in silico data-mining indicated that all of the GNA12-regulated hub and bottleneck nodes identified here such as AKT, VEGFA, BCL2L1, TGFB1, IGF1, and GHRH are associated with poor prognosis in ovarian cancer (78‑83).

A new paradigm emerging from the current analysis showed the potential role of GNA12 in suppressing the proteasome pathway. It is of interest to note that the proteasomal proteolytic machinery has been reported to be required for the rapid onset of death receptor-induced apoptosis in a context-specific manner (47,48). In fact, it has been documented that the overexpression of PSMA6 and PSMC5 was associated with chemoresistance in prostate cancer and radiation-therapy resistance in lung cancer, respectively (49,50). Moreover, ANAPCI, a hub/pathway gene in this network, is part of the APC/C, which is involved in cell cycle arrest at G1 phase. APC/C is an E3-ubiquitin ligase that regulates cell cycle arrest by marking cell cycle proteins, such as cyclins, for degradation by proteasomes during cell cycle exit (53,54). UBE2E1, which was identified here as the hub and pathway gene, encodes an E2-ubiquitin conjugating enzyme. It has been revealed that UBE2E1 can complex with polycomb repressive complex 1 (PRC1), the E3 ligase complex responsible for histone H2A ubiquitination and gene silencing (46). With the established role of PRC1 complex in the silencing of tumor suppressor genes (84), it can be considered that UBE2E1 serves an active role in PRC1-mediated silencing of tumor suppressor genes.

One of the hallmarks of cancer involves metabolic reprogramming in cancer cells, with a shift towards aerobic glycolysis. It is known that along with the glycolytic shift, cancer cells concomitantly suppress mitochondrial oxidative phosphorylation (85). While the mechanism via which cancer cells proactively resort to glycolytic shift is beginning to be understood, the role of an active signaling mechanism involved in suppressing oxidative phosphorylation has thus far remained uncharacterized. In this regard, NDUFA4 and NDUFB8, which have been identified as bottleneck genes in the GNA12-suppressed network, are highly relevant. NDUFA4 and NDUFB8 are subunits of complex IV and complex I of the mitochondrial electron transport chain, and are essential components involved in mitochondrial oxidative phosphorylation (86‑88). The decreased expression of NDUFA4 has been correlated with the suppression of oxidative phosphorylation and stimulation of glycolysis in renal cancer patients; confers resistance to paclitaxel. (33)

Table V. Hub and bottleneck genes downregulated in GNA12-silenced cells.

| Genes   | Nodes            | Function                                                                 | (Refs.) |
|---------|------------------|--------------------------------------------------------------------------|---------|
| AKT     | Hub and bottleneck | Amplified in ovarian cancer patients; confers resistance to paclitaxel.   | (33)    |
| VEGFA   | Hub and bottleneck | Overexpression in ovarian cancer patients; tumor angiogenesis, associated with distant metastasis and resistance to chemotherapy. | (34‑36) |
| STAT3   | Hub and bottleneck | Tumor cell growth; survival, growth, stemness and tumor angiogenesis.     | (41)    |
| BCL2L1  | Hub              | Anti-apoptosis; confers platinum resistance.                              | (39,40) |
| TGFB1   | Hub              | Tumor growth, epithelial-mesenchymal transition and metastasis.           | (37,38) |
| IGF1    | Bottleneck       | Overexpressed in ovarian cancer; tumor cell proliferation; immunosuppressive role. | (42,43) |
| GHRH    | Bottleneck       | Endogenous synthesis in ovarian cancer cells; ovarian cancer growth; tumor vascularization. | (44,45) |

GNA12, G protein subunit α 12; IGF1, insulin-like growth factor 1; GHRH, growth hormone-releasing hormone.
Similarly, low expression of NDUFB8 has been associated with impaired oxidative phosphorylation, along with a shift towards aerobic glycolysis in breast cancer cells (91). These findings, along with the current results that NDUFA4 and NDUFB8 were identified as bottleneck nodes, revealed the previously uncharacterized signaling node via which the LPA/LPAR/GNA12 signaling network could suppress oxidative phosphorylation to promote glycolytic shift in ovarian cancer cells. Thus, taken together, GNA12 appears to promote ovarian cell proliferation by suppressing multi-faceted anti-tumorigenic signaling nodes.

In summary, the present results provided novel insights into the mechanism via which GNA12, stimulated by LPA/LPAR or mutational activation, could coordinate the upregulation of a growth promoting signaling network, while simultaneously regulating the downregulation of a growth-suppressive signaling network, to promote ovarian cancer growth. While the dysregulation of numerous different pathways is known in ovarian cancer, the core signal processing unit that connects the signaling nodes into a coordinated oncogenic network remains unknown. The current study demonstrated such a role for the LPA/LPAR/GNA12 signaling nexus regulated multiple hub and bottleneck nodes of an extensive oncogenic network suggested that this axis may be a potential target for the development of network-targeted combination therapeutic strategies for treating ovarian cancer.

Acknowledgements
Not applicable.

Funding
The present research was supported by a pilot grant from the Stephenson Cancer Center, The Department of Defense Ovarian Cancer Research Program Award (grant no. W81XWH-18-1-0066) and The National Institutes of Health grant (grant no. GM103639). Computational services were supported by The National Institute of General Medical Sciences of the National Institutes of Health.
Sciences P20 (grant no. GM103639) and The National Cancer Institute of the National Institutes of Health (grant no. P30CA225520).

Availability of data and materials
The microarray data presented in the present study are deposited at the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/; accession no. GSE173214. Oncoprint data supporting the reported results used the Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy) dataset available https://www.cbioportal.org.

Authors’ contributions
CI, YSS, JHH, MJ and DND conceptualized the study. MY, JHH and MJ validated the experiments. MY, JHH and PD performed the formal analysis. DND procured resources. MY, MJ, PD and JHH curated and analyzed the data. DND wrote and prepared the original draft. DND, YSS and CI were responsible for writing, revising and editing the manuscript. DND supervised, acquired funds and was project administrator. All authors have read and approved the final version of the manuscript. DND, YSS, MJ, JHH and CI confirm the authenticity of all the raw data.

Ethics approval and consent to participate
Approved by the Institutional Review Board of the University of Oklahoma (approval no. #9599).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jamal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209‑249, 2021.
2. Siegel RL, Miller KD, Fuchs HE and Jamal A: Cancer Statistics, 2021. CA Cancer J Clin 71: 7‑33, 2021.
3. Bast RC Jr, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, Chen JH, Skates SJ et al: Biomarkers and strategies for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 29: 2504‑2512, 2020.
4. Wang Q, Peng H, Qi X, Wu M and Zhao X: Targeted therapies in gynecological cancers: A comprehensive review of clinical evidence. Signal Transduct Target Ther 5: 157, 2020.
5. Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer: Nat Rev Cancer 3: 582‑591, 2003.
6. Cui R, Bai H, Cao G and Zhang Z: The role of lysophosphatidic acid receptors in ovarian cancer: A minireview. Crit Rev Eukaryot Gene Expr 30: 265‑272, 2020.
7. Moolenaar WH: LPA: A novel lipid mediator with diverse biological actions. Trends Cell Biol 4: 213‑219, 1994.
8. Moolenaar WH, van Meeteren LA and Giepmans BN: The ins and outs of lysophosphatidic acid signaling. Bioessays 26: 870‑881, 2004.
9. Noguchi K, Herr D, Mutoh T and Chun J: Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9: 15‑23, 2009.
10. Radhika V and Dhanasekaran N: Transforming G proteins. Oncogene 20: 1607‑1614, 2001.
11. Goldsmith ZG and Dhanasekaran DN: G protein regulation of MAPK networks. Oncogene 26: 3122‑3142, 2007.
12. Radhakrishnan R, Ha JH and Dhanasekaran DN: Mitogenic signaling by the gep oncopgene involves the upregulation of 5‑phase kinase‑associated protein 2. Genes Cancer 1: 1033‑1043, 2010.
13. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P et al: LPA induces metabolic reprogramming in ovarian cancer via a pseudohypoxic response. Cancer Res 78: 1923‑1934, 2018.
14. Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS and Dhanasekaran DN: Ovarian cancer cell‑derived lysophosphatidic acid induces glycolytic shift and cancer‑associated fibroblast‑phenotype in normal and peritumoral fibroblasts. Cancer Lett 442: 464‑474, 2019.
15. Goldsmith ZG, Ha JH, Jayaraman M and Dhanasekaran DN: Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto‑oncopgene Galphai(12). Genes Cancer 2: 563‑575, 2011.
16. Ha JH, Gomathinayagam R, Yan M, Jayaraman M, Ramesh R and Dhanasekaran DN: Determinant role for the gep oncopgenes, Galpha12/13, in ovarian cancer cell proliferation and xenograft tumor growth. Genes Cancer 6: 356‑364, 2015.
17. Juneja J and Casey PF: Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol 158: 32‑40, 2009.
18. Kelly P, Stemmlle LN, Madden JF, Fields TA, Daaka Y and Casey PF: A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 281: 24483‑24490, 2006.
19. Kelly P, Moessler BJ, Juneja J, Booden MA, Der CJ, Daaka Y, Dewhirst MW, Fields TA and Casey PJ: The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci USA 103: 8173‑8178, 2006.
20. Liu SC, Jen YM, Jiang SS, Chang JL, Hsiung CA, Wang CH and Jiang JL: (Galphia2)/mediated pathway promotes invasiveness of nasopharyngeal carcinoma by modulating actin cytoskeleton reorganization. Cancer Res 69: 6122‑6130, 2009.
21. Wuchty S, Zhang A, Walling J, Ahn S, Li A, Quezado M, Oberholtzer C, Zenklusen JC and Fine HA: Gene pathways and subnetworks distinguish between major glioma subtypes and elucidate potential underlying biology. J Biomed Inform 43: 945‑952, 2010.
22. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID Bioinformatics Resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35: W169‑W175, 2007.
23. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta‑Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P et al: STRING v11: Protein‑protein association networks with increased coverage, supporting functional discovery in genome‑wide experimental datasets. Nucleic Acids Res 47: D607‑D613, 2019.
24. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of molecular interaction networks. Genome Res 13: 2498‑2504, 2003.
25. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: cyto‑Hubba: Identifying hub objects and sub‑networks from complex interactome. BMC Syst Biol 8 (Suppl 6): S11, 2014.
26. Liu Z, Meng J, Li X, Zhu F, Liu T, Wu G and Zhang L: Identification of hub genes and key pathways associated with two subtypes of diffuse large B‑cell lymphoma based on gene expression profiling via integrated bioinformatics. Biomed Res Int 2018: 357453, 2018.
27. Vogler O, Barcelo JM, Ribas C and Escriba PV: Membrane interactions of G proteins and other related proteins. Biochim Biophys Acta 1778: 1640‑16052, 2008.
28. Solary E, Eymir B, Dron N and Haugy M: Proteases, proteolysis, and apoptosis. Cell Biol Toxicol 14: 121‑132, 1998.
29. Yu H, Kim PM, Sprecher E, Trifonov V and Gerstein M: The importance of bottlenecks in protein networks: Correlation with gene essentiality and expression dynamics. PLoS Comput Biol 3: e59, 2007.
30. Angstou T, Bryan K and Lynn DJ: Using biological networks to integrate, visualize and analyze genomics data. Genet Sel Evol 48: 27, 2016.
Transcriptomic analysis reveals Overexpression of CD157 contributes to A Novel antagonistic role in the brain. Proc Natl Acad Sci USA 102: 862-867, 2005.

Hou DL, Chen L, Liu B, Song LN and Fang T: Identification of common gene networks responsive to radiotherapy in human ovarian cancer cells. Cancer Gene Ther 21: 542-548, 2014.

Shim E, Shim H, Bae J, Lee H and Jeoung D: CAGE displays oncogenic potential and induces cytolytic T lymphocyte activity. Biotechnol Lett 28: 515-520, 2006.

Takahashi A, Seike M, Chiba M, Takahashi S, Nakamichi S, Matsumoto M, Takeuchi S, Minegishi Y, Noro R, Kunugi S, et al: Ankyrin repeat domain 1 overexpression is associated with common resistance to afatinib and osimertinib in EGFR-mutant non–small cell lung cancer. Sci Rep 8: 14896, 2018.

Shim E, Shin H, Hae B, Lee H and Jeoung D: CAGE displays oncogenic potential and induces cytolytic T lymphocyte activity. Biotechnol Lett 28: 515-520, 2006.

Vessey MP, Daling JR, Brownson RC, Dunson DB, Garfinkel L, Kato I, Kirschenbaum B, Koster JR, Peipert JF, et al: The effect of hormone replacement therapy on breast cancer risk: A collaborative re-analysis. Lancet Oncol 12: 681-691, 2011.

Vessey MP, Daling JR, Brownson RC, Dunson DB, Garfinkel L, Kato I, Kirschenbaum B, Koster JR, Peipert JF, et al: The effect of hormone replacement therapy on breast cancer risk: A collaborative re-analysis. Lancet Oncol 12: 681-691, 2011.

Vessey MP, Daling JR, Brownson RC, Dunson DB, Garfinkel L, Kato I, Kirschenbaum B, Koster JR, Peipert JF, et al: The effect of hormone replacement therapy on breast cancer risk: A collaborative re-analysis. Lancet Oncol 12: 681-691, 2011.

Vessey MP, Daling JR, Brownson RC, Dunson DB, Garfinkel L, Kato I, Kirschenbaum B, Koster JR, Peipert JF, et al: The effect of hormone replacement therapy on breast cancer risk: A collaborative re-analysis. Lancet Oncol 12: 681-691, 2011.

Vessey MP, Daling JR, Brownson RC, Dunson DB, Garfinkel L, Kato I, Kirschenbaum B, Koster JR, Peipert JF, et al: The effect of hormone replacement therapy on breast cancer risk: A collaborative re-analysis. Lancet Oncol 12: 681-691, 2011.

Vessey MP, Daling JR, Brownson RC, Dunson DB, Garfinkel L, Kato I, Kirschenbaum B, Koster JR, Peipert JF, et al: The effect of hormone replacement therapy on breast cancer risk: A collaborative re-analysis. Lancet Oncol 12: 681-691, 2011.

Vessey MP, Daling JR, Brownson RC, Dunson DB, Garfinkel L, Kato I, Kirschenbaum B, Koster JR, Peipert JF, et al: The effect of hormone replacement therapy on breast cancer risk: A collaborative re-analysis. Lancet Oncol 12: 681-691, 2011.
NDUFA4 expression in Arabidopsis flower and embryo development. NDUFA4 is a subunit of the mitochondrial respiratory chain complex IV. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84: 582-589, 1999.